Abzena
Abzena is a leading biopharmaceutical CDMO + CRO specializing in complex biologics and bioconjugates, offering integrated drug discovery, development, and GMP manufacturing services. With over 20 years of expertise, they support programs across modalities including mAbs, ADCs, AOCs, RDCs, fusion proteins, and bispecifics, backed by robust analytical capabilities. Their mission is to enable the development of life-changing medicines by providing tailored solutions, streamlining development timelines, and ensuring high-quality data and regulatory support.
Industries
Nr. of Employees
large (251-1000)
Abzena
San Diego, California, United States, North America
Products
High-yield cell line development platform
Platform workflow for accelerated cell line development and selection to produce high-expressing manufacturing cell lines and early material.
Immunogenicity assessment platform
Suite combining bioinformatic epitope analysis with primary human cell-based assays for immunogenicity risk evaluation.
Analytical data aggregation and reporting platform
Platform for rapid collection, processing and visualization of analytical data to speed decision-making during development.
Antibody humanization and deimmunization platform
Platform to humanize antibody sequences and design deimmunized protein sequences to reduce predicted immunogenicity while preserving function.
Site-selective conjugation technology
Conjugation methodology enabling controlled, site-specific attachment of payloads to biologics to improve conjugate homogeneity and performance.
Developability assessment service
Analytical and computational assessment to identify developability liabilities and to prioritize design choices early in drug development.
High-yield cell line development platform
Platform workflow for accelerated cell line development and selection to produce high-expressing manufacturing cell lines and early material.
Immunogenicity assessment platform
Suite combining bioinformatic epitope analysis with primary human cell-based assays for immunogenicity risk evaluation.
Analytical data aggregation and reporting platform
Platform for rapid collection, processing and visualization of analytical data to speed decision-making during development.
Antibody humanization and deimmunization platform
Platform to humanize antibody sequences and design deimmunized protein sequences to reduce predicted immunogenicity while preserving function.
Site-selective conjugation technology
Conjugation methodology enabling controlled, site-specific attachment of payloads to biologics to improve conjugate homogeneity and performance.
Developability assessment service
Analytical and computational assessment to identify developability liabilities and to prioritize design choices early in drug development.
Services
End-to-end services combining discovery, preclinical and clinical development with GMP manufacturing for biologics and bioconjugates.
Design and synthesis of linkers and payloads, conjugation method development and characterization to support ADC, AOC and radionuclide conjugate programs.
Discovery workflows including sequencing, protein engineering (humanization, deimmunization) and developability screening to prioritize candidates.
Rapid cell line development and provision of early material to enable timely progression to clinical manufacturing.
Development and validation of analytical and bioassay methods including immunogenicity assessments and functional assays to support regulatory filings.
Customized formulation development for biologics and conjugates in liquid and lyophilized formats with stability program design.
End-to-end services combining discovery, preclinical and clinical development with GMP manufacturing for biologics and bioconjugates.
Design and synthesis of linkers and payloads, conjugation method development and characterization to support ADC, AOC and radionuclide conjugate programs.
Discovery workflows including sequencing, protein engineering (humanization, deimmunization) and developability screening to prioritize candidates.
Rapid cell line development and provision of early material to enable timely progression to clinical manufacturing.
Development and validation of analytical and bioassay methods including immunogenicity assessments and functional assays to support regulatory filings.
Customized formulation development for biologics and conjugates in liquid and lyophilized formats with stability program design.
Expertise Areas
- Integrated CDMO and CRO services for complex biologics and bioconjugates
- Antibody discovery, engineering, humanization and deimmunization
- Bioconjugate (ADC, AOC, RDC) design, linker–payload chemistry and site-selective conjugation
- Cell line development and CHO cell engineering
Key Technologies
- CHO cell line development platforms
- Sequence-based antibody discovery and engineering
- Site-specific conjugation chemistries
- Linker and payload synthesis for bioconjugates